Sage Therapeutics/$SAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sage Therapeutics
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Ticker
$SAGE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
353
ISIN
US78667J1088
Website
SAGE Metrics
BasicAdvanced
$572M
-
-$5.79
0.48
-
Price and volume
Market cap
$572M
Beta
0.48
52-week high
$13.47
52-week low
$4.62
Average daily volume
2.5M
Financial strength
Current ratio
9.13
Quick ratio
8.785
Long term debt to equity
2.45
Total debt to equity
2.893
Profitability
EBITDA (TTM)
-358.976
Gross margin (TTM)
-291.84%
Net profit margin (TTM)
-747.61%
Operating margin (TTM)
-758.97%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-36.35%
Return on equity (TTM)
-63.53%
Valuation
Price to revenue (TTM)
11.799
Price to book
1.39
Price to tangible book (TTM)
1.39
Price to free cash flow (TTM)
-1.798
Free cash flow yield (TTM)
-55.62%
Free cash flow per share (TTM)
-508.35%
Growth
Revenue change (TTM)
-47.94%
Earnings per share change (TTM)
-31.00%
3-year revenue growth (CAGR)
95.88%
3-year earnings per share growth (CAGR)
-11.05%
10-year earnings per share growth (CAGR)
13.04%
What the Analysts think about SAGE
Analyst ratings (Buy, Hold, Sell) for Sage Therapeutics stock.
Bulls say / Bears say
Supernus Pharmaceuticals' acquisition of Sage Therapeutics for up to $795 million provides a significant cash infusion and strategic support, potentially accelerating the development and commercialization of Sage's pipeline products. (reuters.com)
Sage's postpartum depression drug, Zurzuvae, co-developed with Biogen, generated $36.1 million in sales in 2024 and $13.8 million in Q1 2025, indicating strong market acceptance and revenue potential. (reuters.com)
The acquisition by Supernus is expected to yield annual cost savings of up to $200 million, enhancing operational efficiency and profitability. (reuters.com)
Sage's revenue declined by 52.3% in 2024 compared to the previous year, raising concerns about the company's financial stability and growth prospects. (stockanalysis.com)
Analysts have lowered their price targets for Sage, with Piper Sandler reducing it from $26.00 to $9.00, reflecting diminished confidence in the company's valuation. (etfdailynews.com)
Sage's stock experienced a significant decline of nearly 75% last year due to multiple trial failures, indicating potential challenges in its drug development pipeline. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
SAGE Financial Performance
Revenues and expenses
SAGE Earnings Performance
Company profitability
SAGE News
AllArticlesVideos
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·4 days ago
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. (NASDAQ: SAGE)
GlobeNewsWire·2 weeks ago
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sage Therapeutics stock?
Sage Therapeutics (SAGE) has a market cap of $572M as of July 18, 2025.
What is the P/E ratio for Sage Therapeutics stock?
The price to earnings (P/E) ratio for Sage Therapeutics (SAGE) stock is 0 as of July 18, 2025.
Does Sage Therapeutics stock pay dividends?
No, Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Sage Therapeutics dividend payment date?
Sage Therapeutics (SAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Sage Therapeutics?
Sage Therapeutics (SAGE) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.